JP4954170B2 - 舌下、頬発泡薬 - Google Patents
舌下、頬発泡薬 Download PDFInfo
- Publication number
- JP4954170B2 JP4954170B2 JP2008246357A JP2008246357A JP4954170B2 JP 4954170 B2 JP4954170 B2 JP 4954170B2 JP 2008246357 A JP2008246357 A JP 2008246357A JP 2008246357 A JP2008246357 A JP 2008246357A JP 4954170 B2 JP4954170 B2 JP 4954170B2
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- fentanyl
- amount
- dosage form
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
1.粘膜層の厚さ及び/または粘度の減少
2.緊密接合の変化
3.細胞膜構造の変化の誘因
4.細胞膜内の疎水環境の増大
タブレットは、直接圧縮、湿式造粒その他のタブレット製造技術により製造することができる。例えば、米国特許第5,178,878号及び同第5,223、264号を参照されたい。タブレットは、バイオ接着層と発泡剤層との間に活性成分の層が挟まれてなる層状タブレットとすることができる。異なる組成物の層に上記した成分を含む他の層状形態物とすることもできる。
発泡剤のレベル: 5%−95%
タブレットのサイズ:約4.8mm−15.9mm(3/16”−5/8”)
タブレットの硬度: 5N乃至80N
投与のルート: 舌下、頬、歯肉
短い フェンタニル、クエン酸塩、USP 1.57
崩壊 ラクトース一水和物 119.47
時間 微結晶セルロース、珪化物 119.47
炭酸ナトリウム、無水物 46.99
炭酸水素ナトリウム 105
クエン酸塩、無水物 75
ポリビニルピロリドン、架橋 25
ステアリン酸マグネシウム 5
コロイド状二酸化珪素 2.5
タブレットの全質量 500
長い クエン酸フェンタニル、USP 1.57
崩壊 ラクトース一水和物 270.93
時間 炭酸ナトリウム、無水物 40.00
炭酸水素ナトリウム 105
クエン酸、無水物 75
ステアリン酸マグネシウム 5
コロイド状二酸化珪素 2.5
タブレットの全質量 500
頬 プロクロルペラジン 5.00
炭酸水素ナトリウム 15.52
クエン酸、無水物 11.08
炭酸水素ナトリウム 45.78
HPMC K4M プレム(prem) 5.00
燐酸二カルシウム二水和物 5.00
マンニトール 11.67
ステアリン酸マグネシウム 0.95
合計 100.00
舌下 プロクロルペラジン 5.00
炭酸水素ナトリウム 61.25
クエン酸、無水物 43.75
炭酸水素ナトリウム 95
炭酸ナトリウム 91.25
HPMC メトセル(methocel) K4M プレム 40
マンニトール 60
ステアリン酸マグネシウム 3.75
合計 400
Claims (26)
- 口内粘膜を介してフェンタニルの増進した頬、舌下または歯肉投与に適したタブレットであって、
(a)頬、舌下および歯肉投与を含む、口内粘膜を介する経口投与において有効量のフェンタニルまたはその医薬的に許容される塩;
(b)当該フェンタニルの治療的に有効な濃度が非イオン化形態で存在することを可能にする量の少なくとも1種のpH調整物質;および
(c)タブレット崩壊に必要な量以上であって、口内粘膜を介して当該フェンタニルの吸収を増進するに十分な量で存在する、少なくとも1種の唾液活性化発泡剤(effervescent couple)(ただし、当該少なくとも1種の発泡剤の量はタブレットの5〜80重量%である)
を含む、タブレット。 - 当該発泡剤が20〜80重量%の量で存在する、請求項1記載のタブレット。
- 当該発泡剤が30〜80重量%の量で存在する、請求項2記載のタブレット。
- 非発泡性透過促進剤をさらに含む、請求項1〜3のいずれか記載のタブレット。
- バイオ接着剤をさらに含む、請求項1〜4のいずれか記載のタブレット。
- 非発泡性崩壊剤をさらに含む、請求項1〜5のいずれか記載のタブレット。
- グライダント、滑剤、バインダ、甘味剤、風味成分および着色成分の少なくとも1種をさらに含む、請求項1〜6のいずれか記載のタブレット。
- 口内粘膜を介してフェンタニルの増進した頬、舌下または歯肉投与に適したタブレットであって、
(a)口内粘膜を介する経口投与のための、口内においてイオン化形態および非イオン化形態で存在することが出来る、医薬的に有効量のフェンタニルまたはその医薬的に許容される塩;
(b)タブレット崩壊に必要な量以上であって、口内粘膜を介して当該フェンタニルの吸収を増進するに十分な量で存在する、少なくとも1種の唾液活性化発泡剤;および
(c)口内の吸収部位において当該タブレットの局所的環境のpHが当該フェンタニルの非イオン化形態に好ましいように変化させるに十分な量で存在する、少なくとも1種のpH調整物質
を含む、タブレット。 - グライダント、滑剤、バインダ、甘味剤、風味成分、非発泡性崩壊剤および着色成分の少なくとも1種をさらに含む、請求項8記載のタブレット。
- タブレットと口内粘膜の接触時間を増進させる、バイオ接着剤をさらに含む、請求項8記載のタブレット。
- 微結晶セルロース、クロスカルメロースナトリウム、クロスポビドン、澱粉、とうもろこし澱粉、じゃがいも澱粉、改質とうもろこし澱粉、改質じゃがいも澱粉、ベントナイト、アルギン酸塩、寒天、グアー、ローカストビーン、カラヤ、ペクチンおよびトラガントから選択される非発泡性崩壊剤をさらに含む、請求項8記載のタブレット。
- 当該少なくとも1種の唾液活性化発泡剤が20〜80重量%の量で存在する、請求項8記載のタブレット。
- 当該少なくとも1種の唾液活性化発泡剤が5〜80重量%の量で存在する、請求項8記載のタブレット。
- 当該pH調整物質が炭酸ナトリウム、炭酸カリウム、炭酸マグネシウム、燐酸水素二ナトリウム、燐酸二水素ナトリウム、燐酸水素二カリウムおよび燐酸二水素カリウムからなる群から選択される塩基である、請求項1または8記載のタブレット。
- 当該pH調整物質が口内の吸収部位で当該フェンタニルの局所環境のpHを変化させるに十分な量で存在する、請求項1記載のタブレット。
- 頬投与に適した、請求項1記載のタブレット。
- 歯肉投与に適した、請求項1記載のタブレット。
- 舌下投与に適した、請求項1記載のタブレット。
- 口内粘膜を介するフェンタニルまたはその医薬的に許容される塩の頬、舌下または歯肉投与に適した固形製剤投与形であって、
(a)口内粘膜を介する経口投与で有効量のフェンタニルまたはその医薬的に許容される塩、(b)口内粘膜を介する当該フェンタニルの医薬的有効量の吸収を増進させるに十分な量であって、その量が約5〜80重量%の範囲にある少なくとも1種の唾液活性化発泡剤、および(c)少なくとも1種のpH調整剤
を含む投与形。 - 当該pH調整剤が塩基である、請求項19記載の投与形。
- 当該塩基が炭酸ナトリウム、炭酸カリウム、炭酸マグネシウム、燐酸水素二ナトリウム、燐酸二水素ナトリウム、燐酸水素二カリウムおよび燐酸二水素カリウムからなる群から選択される、請求項20記載の投与形。
- 非発泡性崩壊剤をさらに含む、請求項19記載の投与形。
- 非発泡性崩壊剤が微結晶セルロース、クロスカルメロースナトリウム、クロスポビドン、澱粉、とうもろこし澱粉、じゃがいも澱粉、改質とうもろこし澱粉、改質じゃがいも澱粉、ベントナイト、アルギン酸塩、寒天、グアー、ローカストビーン、カラヤ、ペクチンおよびトラガントから成る群から選択される、請求項22記載の投与形。
- バイオ接着剤をさらに含む、請求項19記載の投与形。
- グライダント、滑剤、バインダ、甘味剤、風味成分および着色成分からなる群から選択される少なくとも1種をさらに含む、請求項19記載の投与形。
- フェンタニルの医薬的に許容される塩がフェンタニルクエン酸塩である、請求項19記載の投与形。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27742499A | 1999-03-26 | 1999-03-26 | |
US09/277,424 | 1999-03-26 | ||
US09/327,814 | 1999-06-08 | ||
US09/327,814 US6200604B1 (en) | 1998-03-27 | 1999-06-08 | Sublingual buccal effervescent |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000607609A Division JP4789324B2 (ja) | 1999-03-26 | 2000-03-22 | 舌下、頬発泡薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009029829A JP2009029829A (ja) | 2009-02-12 |
JP4954170B2 true JP4954170B2 (ja) | 2012-06-13 |
Family
ID=26958475
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000607609A Expired - Lifetime JP4789324B2 (ja) | 1999-03-26 | 2000-03-22 | 舌下、頬発泡薬 |
JP2008246357A Expired - Lifetime JP4954170B2 (ja) | 1999-03-26 | 2008-09-25 | 舌下、頬発泡薬 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000607609A Expired - Lifetime JP4789324B2 (ja) | 1999-03-26 | 2000-03-22 | 舌下、頬発泡薬 |
Country Status (13)
Country | Link |
---|---|
US (1) | US6200604B1 (ja) |
EP (4) | EP2095813B1 (ja) |
JP (2) | JP4789324B2 (ja) |
AT (4) | ATE434432T1 (ja) |
AU (1) | AU4019400A (ja) |
CA (2) | CA2569674C (ja) |
CY (3) | CY1107592T1 (ja) |
DE (3) | DE60042427D1 (ja) |
DK (3) | DK1417959T3 (ja) |
ES (3) | ES2276677T3 (ja) |
HK (1) | HK1130691A1 (ja) |
PT (3) | PT1082106E (ja) |
WO (1) | WO2000057858A1 (ja) |
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
US20040023948A1 (en) * | 1997-03-24 | 2004-02-05 | Green Richard David | Fast-dispersing dosage form containing 5-HT1 agonists |
US20030091629A1 (en) * | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
US20030118645A1 (en) * | 1998-04-29 | 2003-06-26 | Pather S. Indiran | Pharmaceutical compositions for rectal and vaginal administration |
US6974590B2 (en) | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
US6358060B2 (en) * | 1998-09-03 | 2002-03-19 | Jsr Llc | Two-stage transmucosal medicine delivery system for symptom relief |
US6531114B1 (en) | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
US6627234B1 (en) | 1998-12-15 | 2003-09-30 | Wm. Wrigley Jr. Company | Method of producing active agent coated chewing gum products |
US7163705B2 (en) * | 1998-12-15 | 2007-01-16 | Wm. Wrigley Jr. Company | Coated chewing gum product and method of making |
US6355265B1 (en) | 1999-04-06 | 2002-03-12 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations |
US6426090B1 (en) | 1999-04-06 | 2002-07-30 | Wm. Wrigley Jr. Company | Over-coated product including tableted center and medicament |
US7935362B2 (en) * | 1999-04-06 | 2011-05-03 | Wm. Wrigley Jr. Company | Over-coated product including consumable center and medicament |
US20020159956A1 (en) * | 1999-04-06 | 2002-10-31 | Ream Ronald L. | Over-coated chewing gum formulations |
US6773716B2 (en) | 1999-04-06 | 2004-08-10 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations |
WO2001021156A1 (en) * | 1999-04-06 | 2001-03-29 | Wm. Wrigley Jr. Company | Pharmaceutical chewing gum formulations |
US6541048B2 (en) | 1999-09-02 | 2003-04-01 | Wm. Wrigley Jr. Company | Coated chewing gum products containing an acid blocker and process of preparing |
US6569472B1 (en) | 2000-09-01 | 2003-05-27 | Wm. Wrigley Jr. Company | Coated chewing gum products containing antacid and method of making |
US6645535B2 (en) | 1999-09-02 | 2003-11-11 | Wm. Wrigley Jr. Company | Method of making coated chewing gum products containing various antacids |
US6663849B1 (en) | 2000-09-01 | 2003-12-16 | Wm. Wrigley Jr. Company | Antacid chewing gum products coated with high viscosity materials |
WO2001021147A1 (en) * | 1999-09-20 | 2001-03-29 | Mastercare | Diet and weight control gum and sucker |
US9387168B2 (en) | 1999-09-20 | 2016-07-12 | Jack Barreca | Chewing gum with tomatidine |
US9253991B2 (en) | 1999-09-20 | 2016-02-09 | Jack Barreca | Chewing gum with B vitamins |
CN1407884B (zh) | 1999-10-29 | 2012-06-20 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
AU2001261744A1 (en) * | 2000-05-19 | 2001-12-03 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
US7115288B2 (en) * | 2000-06-09 | 2006-10-03 | Wm. Wrigley Jr. Company | Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener |
US6572900B1 (en) | 2000-06-09 | 2003-06-03 | Wm. Wrigley, Jr. Company | Method for making coated chewing gum products including a high-intensity sweetener |
MXPA03003895A (es) | 2000-10-30 | 2003-07-28 | Euro Celtique Sa | Formulaciones de hidrocodona de liberacion controlada. |
AU2002221412B2 (en) * | 2000-12-05 | 2006-04-13 | Alexander Macgregor | Hydrostatic delivery system for controlled delivery of agent |
US7799342B2 (en) * | 2000-12-06 | 2010-09-21 | Wyeth Llc | Fast dissolving tablet |
US6579545B2 (en) | 2000-12-22 | 2003-06-17 | Wm. Wrigley Jr. Company | Coated chewing gum products containing an antigas agent |
US7062312B2 (en) * | 2001-01-17 | 2006-06-13 | Pediamed Pharmaceuticals, Inc. | Combination and method including a visual marker for determining compliance with a medication regimen |
US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
US6613346B2 (en) | 2001-06-28 | 2003-09-02 | Wm. Wrigley, Jr. Company | Chewable product including active ingredient |
US6685951B2 (en) | 2001-07-05 | 2004-02-03 | R. T. Alamo Ventures I, Inc. | Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine |
US20030022910A1 (en) * | 2001-07-05 | 2003-01-30 | R.T. Alamo Ventures I, Inc. | Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine |
US20030198669A1 (en) * | 2001-07-05 | 2003-10-23 | R.T. Alamo Ventures I, Llc | Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine |
US20030017175A1 (en) * | 2001-07-05 | 2003-01-23 | R.T. Alamo Ventures I, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
US20030068356A1 (en) * | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
RU2004107501A (ru) * | 2001-08-14 | 2005-02-20 | Байотай Терапис Корпорейшн (Fi) | Способ лечения алкоголизма или злоупотребления алкоголем |
US20030083286A1 (en) * | 2001-08-22 | 2003-05-01 | Ching-Leou Teng | Bioadhesive compositions and methods for enhanced intestinal drug absorption |
US20030124196A1 (en) * | 2001-08-22 | 2003-07-03 | Susan Weinbach | Pulsatile release compositions and methods for enhanced intestinal drug absorption |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
DE10224607B4 (de) * | 2002-06-04 | 2008-03-13 | Lts Lohmann Therapie-Systeme Ag | Filmförmige, zerfallsfähige Zubereitungen zur Wirkstofffreisetzung und Verfahren zu deren Herstellung |
US20030235613A1 (en) | 2002-06-19 | 2003-12-25 | Cts Chemical Industries Ltd. | Popping oral administration form |
SI21221A (sl) * | 2002-06-21 | 2003-12-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Hitro razpadljive tablete |
GB0217056D0 (en) * | 2002-07-23 | 2002-08-28 | Ass Octel | Use |
US20080213363A1 (en) * | 2003-01-23 | 2008-09-04 | Singh Nikhilesh N | Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa |
BG730Y1 (bg) * | 2003-03-20 | 2005-04-30 | Владимир НАЙДЕНОВ | Ефервесцентна лекарствена форма |
US20040191345A1 (en) * | 2003-03-26 | 2004-09-30 | Fredrik Nicklasson | New formulations and use thereof |
US20040223921A1 (en) * | 2003-05-07 | 2004-11-11 | Rau Allen H. | Oral care tablet |
US7306812B2 (en) | 2003-05-09 | 2007-12-11 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
US7276246B2 (en) * | 2003-05-09 | 2007-10-02 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
US20050065175A1 (en) * | 2003-09-24 | 2005-03-24 | Xanodyne Pharmacal, Inc. | Oral transmucosal methadone |
CA2545194C (en) | 2003-11-10 | 2014-10-21 | Seymour H. Fein | Pharmaceutical compositions including low dosages of desmopressin |
DE20321887U1 (de) | 2003-11-10 | 2012-01-20 | Allergan, Inc. | Arzneimittel umfassend niedrige Dosierungen von Desmopressin |
US20070036853A1 (en) * | 2003-12-31 | 2007-02-15 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
UA91824C2 (ru) * | 2003-12-31 | 2010-09-10 | Сайма Лебс Инк. | Преимущественно линейная шипучая лекарственная форма фентанила для перорального применения и способы введения |
WO2005065317A2 (en) * | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
EP1708685B1 (en) * | 2003-12-31 | 2011-03-09 | Cima Labs Inc. | Effervescent oral opiate dosage forms and methods of administering oxycodone |
PT1708686E (pt) * | 2003-12-31 | 2011-04-20 | Cima Labs Inc | Forma de dosagem de fentanil oral efervescente geralmente linear e métodos de administração |
EP1715853A4 (en) * | 2004-02-17 | 2012-07-18 | Transcept Pharmaceuticals Inc | COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF |
GB0423800D0 (en) | 2004-10-27 | 2004-12-01 | Orexo Ab | New pharmaceutical formulations |
FR2883179B1 (fr) * | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
KR20130042041A (ko) * | 2005-05-25 | 2013-04-25 | 트랜스셉트 파마슈티칼스, 인코포레이티드 | 야반 불면증을 치료하기 위한 고체 조성물 및 방법 |
US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
US20070287740A1 (en) * | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
US20070020186A1 (en) * | 2005-07-22 | 2007-01-25 | Alpex Pharma S.A. | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
US20070093471A1 (en) * | 2005-10-26 | 2007-04-26 | Alamo Pharmaceuticals, Llc | Compositions and methods for the administration clozapine formulations which modulate body weight |
US20070092586A1 (en) * | 2005-10-26 | 2007-04-26 | Alamo Pharmaceuticals | Compositions and methods for the administration psychotropic drugs which modulate body weight |
CA2629046C (en) * | 2005-12-13 | 2014-04-08 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
US8202535B2 (en) * | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8252328B2 (en) * | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US9289583B2 (en) * | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US9066847B2 (en) * | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US20070260491A1 (en) * | 2006-05-08 | 2007-11-08 | Pamela Palmer | System for delivery and monitoring of administration of controlled substances |
US20100233257A1 (en) * | 2006-06-09 | 2010-09-16 | Ethypharm | Low dose sublingual tablets of opioid analgesics and preparation process |
US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
US20070299687A1 (en) * | 2006-06-23 | 2007-12-27 | Pamela Palmer | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed |
CN103550136B (zh) | 2006-07-21 | 2016-04-13 | 生物递送科学国际公司 | 吸收增强的经粘膜递送装置 |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
US20080090874A1 (en) * | 2006-09-20 | 2008-04-17 | Messina John C Jr | Treatment of breakthrough pain in patients suffering from chronic low back pain |
WO2008067549A2 (en) * | 2006-11-30 | 2008-06-05 | Transcept Pharmaceuticals, Inc. | Stabilized zolpidem pharmaceutical compositions |
US20090214442A1 (en) * | 2006-12-01 | 2009-08-27 | Cephalon, Inc. | Oral Transmucosal Nicotine Dosage Form |
WO2008069921A2 (en) * | 2006-12-01 | 2008-06-12 | Cima Labs Inc. | Oral transmucosal nicotine dosage form |
MX2009006672A (es) | 2006-12-19 | 2009-10-26 | Univ Virginia | Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol. |
EP2112923A1 (en) | 2007-01-22 | 2009-11-04 | Targacept Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
US20080287494A1 (en) * | 2007-04-24 | 2008-11-20 | Cephalon, Inc. | Transmucosal treatment methods in patients with mucositis |
EP2316472A1 (en) * | 2007-05-01 | 2011-05-04 | Cephalon, Inc. | Composition for transmucosal delivery of polypeptides |
ES2663777T3 (es) * | 2008-06-23 | 2018-04-17 | Biodelivery Sciences International, Inc. | Dispositivos de administración mucosa multidireccionales y métodos de uso |
US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
KR101004205B1 (ko) * | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
US20130213393A1 (en) | 2009-12-22 | 2013-08-22 | Evoke Pharma, Inc. | Nasal formulations of metoclopramide |
ES2641821T3 (es) | 2009-10-30 | 2017-11-14 | Ix Biopharma Ltd | Forma de dosificación sólida de disolución rápida |
JP2013526523A (ja) | 2010-05-11 | 2013-06-24 | シマ ラブス インク. | メトプロロールを含むアルコール耐性持続放出性経口剤形 |
HUE035574T2 (en) | 2010-07-02 | 2018-05-28 | Univ Virginia Patent Foundation | Molecular genetic approach to treatment and diagnosis of alcohol and drug addiction |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
WO2012075455A2 (en) | 2010-12-02 | 2012-06-07 | Aptalis Pharmatech, Inc. | Rapidly dispersing granules, orally disintegrating tablets and methods |
WO2012087113A1 (en) * | 2010-12-24 | 2012-06-28 | N.V. Nutricia | Improved nutritional tablet |
BR112013022044A2 (pt) * | 2011-02-28 | 2016-11-29 | Technologies Khlôros Inc | veículo mastigável para absorção na boca |
MX2013013104A (es) | 2011-05-09 | 2014-10-15 | Univ Virginia Patent Found | Composiciones y metodos para el tratamiento de cancer. |
CN103889508B (zh) | 2011-08-18 | 2017-09-12 | 拜欧帝力威瑞科学有限公司 | 用于传递丁丙诺啡的防滥用性粘膜粘附剂装置 |
WO2013036721A1 (en) | 2011-09-09 | 2013-03-14 | University Of Virginia Patent Foundation | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
EP2838516B1 (en) | 2012-04-18 | 2018-10-17 | SpecGx LLC | Immediate release, abuse deterrent pharmaceutical compositions |
PT2968174T (pt) | 2013-03-15 | 2020-01-15 | Braintree Laboratories Inc | Comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e seus métodos de utilização |
MX363844B (es) | 2013-03-15 | 2019-04-05 | SpecGx LLC | Forma de dosificación sólida de disuasivo del abuso para liberación inmediata con marca funcional. |
WO2015063602A1 (en) | 2013-10-29 | 2015-05-07 | Ferring B.V. | Desmopressin and blood glucose |
JP2016535794A (ja) | 2013-11-11 | 2016-11-17 | インパックス ラボラトリーズ,インコーポレーテッド | 急速崩壊性製剤及びその使用法 |
GB2523480B (en) * | 2014-02-07 | 2018-06-27 | Scilabs Pharmaceuticals | All natural, non-toxic sublingual drug delivery systems |
WO2016004170A1 (en) | 2014-07-03 | 2016-01-07 | Mallinckrodt Llc | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides |
WO2016086095A1 (en) | 2014-11-25 | 2016-06-02 | Biodelivery Sciences International, Inc. | Patches, methods for forming and testing pharmaceutical agent delivery patches |
US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
GB2537652A (en) | 2015-04-22 | 2016-10-26 | Cosmetic Warriors Ltd | Composition |
JP6523132B2 (ja) * | 2015-10-20 | 2019-05-29 | リプリーズ バイオファーマシューティクス,エルエルシー | 低用量デスモプレシンを含有する医薬組成物 |
US9855227B2 (en) | 2015-12-18 | 2018-01-02 | The Procter & Gamble Company | Quick dissolving diphenhydramine oral dosage form |
US11173098B1 (en) | 2016-02-05 | 2021-11-16 | Gram Tactical Llc | Magazines for tactical medicine dispensers |
WO2017177037A1 (en) | 2016-04-06 | 2017-10-12 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
BR112018072539A2 (pt) | 2016-05-05 | 2019-03-26 | Aquestive Therapeutics, Inc. | composições de epinefrina de administração aumentada |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
EP3554489A4 (en) | 2016-12-15 | 2020-06-17 | Evoke Pharma, Inc. | TREATMENT OF MODERATE AND SERIOUS GASTROPARESIS |
EP3562486B1 (en) | 2016-12-31 | 2024-03-13 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
US9901545B1 (en) | 2017-04-13 | 2018-02-27 | Richard C. Fuisz | Method and composition for making an oral soluble film, containing at least one active agent |
US10238600B2 (en) | 2017-04-13 | 2019-03-26 | Richard C. Fuisz | Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent |
BR112020026672A2 (pt) | 2018-06-27 | 2021-03-30 | Bioxcel Therapeutics, Inc. | Formulações de filme contendo dexmedetomidina e métodos para produzi-las |
US11478426B2 (en) | 2018-09-25 | 2022-10-25 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
CN109303334B (zh) * | 2018-10-17 | 2021-04-13 | 汤臣倍健股份有限公司 | 一种口腔微泡腾片及其制备方法 |
CA3145388A1 (en) | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
US11173114B1 (en) | 2020-07-10 | 2021-11-16 | Nova Thin Film Pharmaceuticals Llc | Method and system for manufacturing and oral soluble films and oral soluble films made by thereby |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3972995A (en) * | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
US4493848A (en) | 1983-07-14 | 1985-01-15 | The Procter & Gamble Company | Compositions and methods useful for producing analgesia |
US4639368A (en) | 1984-08-23 | 1987-01-27 | Farmacon Research Corporation | Chewing gum containing a medicament and taste maskers |
GB8426152D0 (en) * | 1984-10-16 | 1984-11-21 | Reckitt & Colmann Prod Ltd | Medicinal compositions |
US5135752A (en) * | 1988-10-14 | 1992-08-04 | Zetachron, Inc. | Buccal dosage form |
US5004601A (en) * | 1988-10-14 | 1991-04-02 | Zetachron, Inc. | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith |
US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
WO1991004757A1 (en) | 1989-10-02 | 1991-04-18 | Cima Labs, Inc. | Effervescent dosage form and method of administering same |
US5458879A (en) | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
JP3170139B2 (ja) * | 1994-04-08 | 2001-05-28 | エスエス製薬株式会社 | 発泡性錠剤 |
US5958458A (en) * | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
DK0765157T3 (da) * | 1994-06-15 | 1999-10-25 | Dumex Ltd As | Pellets |
FR2732217B1 (fr) * | 1995-03-29 | 1997-06-06 | Hesnard Xavier | Forme d'administration solide a usage oral |
US5656284A (en) * | 1995-04-24 | 1997-08-12 | Balkin; Michael S. | Oral transmucosal delivery tablet and method of making it |
US5607697A (en) | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
ATE219358T1 (de) * | 1995-11-06 | 2002-07-15 | Somerset Pharmaceuticals Inc | Sublinguale und bukkale verabreichung von selegilin |
US5958455A (en) * | 1996-02-09 | 1999-09-28 | Quadrant Holdings Cambridge Ltd | Oral solid dosage forms, methods of making same and compositions thereof |
DE19618543C2 (de) | 1996-05-08 | 1998-07-02 | Ivoclar Ag | Polymerisationsgerät |
DE19814257A1 (de) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Brauseformulierungen |
WO2000035418A2 (en) * | 1998-12-18 | 2000-06-22 | Bayer Corporation | Chewable drug delivery system |
-
1999
- 1999-06-08 US US09/327,814 patent/US6200604B1/en not_active Expired - Lifetime
-
2000
- 2000-03-22 DK DK03029911T patent/DK1417959T3/da active
- 2000-03-22 AT AT03029877T patent/ATE434432T1/de active
- 2000-03-22 EP EP09008228A patent/EP2095813B1/en not_active Expired - Lifetime
- 2000-03-22 CA CA2569674A patent/CA2569674C/en not_active Expired - Lifetime
- 2000-03-22 DE DE60042427T patent/DE60042427D1/de not_active Expired - Lifetime
- 2000-03-22 PT PT00919523T patent/PT1082106E/pt unknown
- 2000-03-22 JP JP2000607609A patent/JP4789324B2/ja not_active Expired - Lifetime
- 2000-03-22 AT AT00919523T patent/ATE350017T1/de active
- 2000-03-22 CA CA002333375A patent/CA2333375C/en not_active Expired - Lifetime
- 2000-03-22 AT AT09008228T patent/ATE548028T1/de active
- 2000-03-22 EP EP03029877A patent/EP1419765B1/en not_active Expired - Lifetime
- 2000-03-22 PT PT03029877T patent/PT1419765E/pt unknown
- 2000-03-22 DE DE60032691T patent/DE60032691T2/de not_active Expired - Lifetime
- 2000-03-22 ES ES00919523T patent/ES2276677T3/es not_active Expired - Lifetime
- 2000-03-22 EP EP03029911A patent/EP1417959B1/en not_active Expired - Lifetime
- 2000-03-22 EP EP00919523A patent/EP1082106B1/en not_active Expired - Lifetime
- 2000-03-22 ES ES03029877T patent/ES2324907T3/es not_active Expired - Lifetime
- 2000-03-22 DE DE60042463T patent/DE60042463D1/de not_active Expired - Lifetime
- 2000-03-22 AU AU40194/00A patent/AU4019400A/en not_active Abandoned
- 2000-03-22 WO PCT/US2000/007567 patent/WO2000057858A1/en active IP Right Grant
- 2000-03-22 DK DK03029877T patent/DK1419765T3/da active
- 2000-03-22 DK DK00919523T patent/DK1082106T3/da active
- 2000-03-22 AT AT03029911T patent/ATE433745T1/de active
- 2000-03-22 PT PT03029911T patent/PT1417959E/pt unknown
- 2000-03-22 ES ES03029911T patent/ES2324908T3/es not_active Expired - Lifetime
-
2007
- 2007-04-02 CY CY20071100454T patent/CY1107592T1/el unknown
-
2008
- 2008-09-25 JP JP2008246357A patent/JP4954170B2/ja not_active Expired - Lifetime
-
2009
- 2009-06-24 CY CY20091100668T patent/CY1109176T1/el unknown
- 2009-06-25 CY CY20091100667T patent/CY1109172T1/el unknown
- 2009-10-08 HK HK09109341.8A patent/HK1130691A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4954170B2 (ja) | 舌下、頬発泡薬 | |
US8728441B2 (en) | Sublingual buccal effervescent | |
US8802130B2 (en) | Sublingual buccal effervescent | |
EP1837019B1 (en) | Orally-dispersible pharmaceutical compositions | |
WO2007096906A2 (en) | Novel buccoadhesive compositions and process of preparation thereof | |
KR20110097801A (ko) | 구강 삽입용 투여 제형 | |
HU227477B1 (en) | Solid, quick dissolving pharmaceutical compositions containing cetrizine | |
AU2002364468C1 (en) | Solid orally-dispersible pharmaceutical formulation | |
US20080187589A1 (en) | Multi-modal delivery via transmucosal and gastro-intestinal absorption of antihistamines and symptom relief | |
AU2004242477B2 (en) | Sublingual buccal effervescent | |
AU2007203233B2 (en) | Sublingual buccal effervescent | |
ES2383478T3 (es) | Comprimido para administración bucal, sublingual o gingival que comprende un aditivo efervescente | |
JPH10287555A (ja) | チュアブル錠 | |
US20030228370A1 (en) | Orodispersible solid pharmaceutical form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111004 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111226 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120123 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120214 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120313 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4954170 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150323 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |